source
- FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concernsSummit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…
- Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater ChinaPfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…